诚达药业股份有限公司独立董事 二、关于控股股东及其他关联方资金占用和公司对外担保情况的专项说明 经审核，我们认为：2023 年上半年度，公司严格遵守国家法律、法规及规 章制度等相关规定，不存在控股股东及其他关联方违规占用公司资金的情形，也 不存在以前年度发生并延续到 2023 年 6 月 30 日的资金占用情况；2023 年上半 年度未发生对外担保事项，也不存在以前年度发生并延续到 2023 年 6 月 30 日违 规对外担保情况。 （以下无正文） （本页无正文，为《诚达药业股份有限公司独立董事关于第五届董事会第三次会 议相关事项的独立意见》之签字页） 关于第五届董事会第三次会议相关事项的独立意见 根据《上市公司独立董事规则》、《上市公司治理准则》、《深圳证券交易所创 业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》、《公司章程》等有关规定，我们作为诚达药业股份有限公司 （以下简称"公司"）的独立董事，本着谨慎的原则，基于独立判断的立场，对 公司第五届董事会第三次会议审议的相关事项发表如下独立意见： 一、关于《2023 年半年度募集资金存放与使用情况专项报告》的 ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-042 诚达药业股份有限公司 关于召开2023年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2023年第二次临时股东大会 （二）股东大会的召集人：公司董事会 公司于2023年8月21日召开的第五届董事会第三次会议审议通过了《关于召开2023 年第二次临时股东大会的议案》，决议召开本次股东大会。 （三）会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易所业务规则和公司章程等的规定。 （四）会议召开的日期、时间： 1、现场会议时间：2023年9月7日（星期四）下午14：00 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为2023 年9月7日的交易时间，即9:15-9:25、9:30—11:30和13:00—15:00；通过深圳证券交 易所互联网投票的具体时间为：2023年9月7日9:15—15:00。 （五）会议的召开方式：本次股东大会采用现场表决与网络投 ...

证券代码：301201 证券简称：诚达药业 诚达药业股份有限公司 投资者关系活动记录表 编号：2023-003 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | | 线上参与公司2022年度业绩说明会的全体投资者 | | 参与单位名称及人员姓名 | | | 时间 | 2023年05月12日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长 葛建利女士 董事、总经理 卢刚先生 | | | 独立董事 汪萍女士 | | 上市公司接待人员姓名 | 副总经理、董事会秘书 杨晓静女士 | | | 财务总监 费超先生 | | | 保荐代表人 杨科先生 | | | 1.高溢价减持，接盘的是谁？当中有没有利益输送？2.公司有 | | | 没有欺诈发行，股价5月5日比发行价亏损达40%以上？3.公司有没有 | | 投资者关系活动主要内容 | 预期稳定股价的措施 ...

重要内容提示： 证券代码：301201 证券简称：诚达药业 公告编号：2023-025 诚达药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长 葛建利女士，董事、总经理 卢刚先生，独立董事 汪萍女士，副总 经理、董事会秘书 杨晓静女士，财务总监 费超先生，保荐代表人 杨科先生（如 遇特殊情况，参会人员可能进行调整）。 三、投资者参加方式 诚达药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 24 日在巨潮 资讯网（www.cninfo.com.cn）上披露了《2022 年年度报告》及《2022 年年度报 告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司定于 2023 年 5 月 12 日（星期五）15:00-17:00 在"价值在线"（www.ir- online.cn）举办公司 2022 年度业绩说明会，与投资者进行沟通和交流，广泛听取 投资者的意见和建 ...

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 96,696,140 shares[5]. - The company has a profit distribution plan that includes a capital reserve conversion of 6 shares for every 10 shares held by shareholders[5]. - The total distributable profit for the year was RMB 320,243,039.89, with the cash dividend representing 100% of the profit distribution[160]. - The company distributed a cash dividend of RMB 4.50 per 10 shares, totaling RMB 43,513,263, based on a total share capital of 96,696,140 shares for the 2021 fiscal year[158]. - For the 2022 fiscal year, the company plans to distribute a cash dividend of RMB 3.00 per 10 shares, amounting to RMB 29,008,842, while also increasing share capital by 6 shares for every 10 shares held, resulting in a total share capital of 154,713,824 shares[160]. Financial Performance - The company's revenue for 2022 was ¥411,463,537.32, a decrease of 1.03% compared to ¥415,725,787.55 in 2021[26]. - The net profit attributable to shareholders for 2022 was ¥106,484,248.46, representing a 6.02% increase from ¥100,435,615.97 in 2021[26]. - The net profit after deducting non-recurring gains and losses was ¥68,654,409.79, down 28.01% from ¥95,370,415.47 in 2021[26]. - The total assets at the end of 2022 reached ¥2,321,895,635.83, a significant increase of 239.84% from ¥683,227,154.78 at the end of 2021[26]. - The basic earnings per share for 2022 was ¥1.1247, a decrease of 18.79% compared to ¥1.3849 in 2021[26]. - The cash flow from operating activities for 2022 was ¥47,665,536.21, down 42.67% from ¥83,140,534.53 in 2021[26]. - In 2022, the company achieved operating revenue of CNY 411.46 million and a net profit attributable to shareholders of CNY 106.48 million[56]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a 15% year-over-year growth[138]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 20%[198]. Market and Industry Outlook - The company operates in the CDMO industry, which is experiencing rapid growth due to the specialization and globalization of the pharmaceutical industry[36]. - The company plans to expand its market presence in the CDMO sector, focusing on both chemical and biological drug services[36]. - The global pharmaceutical R&D investment increased from $165.1 billion in 2017 to $224.1 billion in 2021, with a CAGR of 7.9%, expected to reach $306.8 billion by 2025 and $417.7 billion by 2030[37]. - The global CDMO market grew from $39.4 billion in 2017 to $63.2 billion in 2021, with a CAGR of 12.5%, projected to reach $124.3 billion by 2025 and $231.0 billion by 2030[37]. - China's CDMO market expanded from ¥13.2 billion in 2017 to ¥47.3 billion in 2021, with a CAGR of 37.7%, anticipated to reach ¥157.1 billion by 2025 and ¥355.9 billion by 2030[38]. - The share of China's CDMO market in the global market increased from 5.0% in 2017 to 13.2% in 2021, expected to account for one-fifth of the global market post-2025[38]. Research and Development - R&D expenses for the year amounted to CNY 19.44 million, representing a year-on-year increase of 12.89%[58]. - The company developed 49 new products during the reporting period, with 3 products passing the Zhejiang Province industrial new product acceptance[58]. - The company is actively pursuing new product development and technological advancements to enhance its competitive edge in the market[36]. - The company is developing a rheumatoid arthritis drug (NP0908-B) with a focus on cost control and environmental issues, aiming to enhance market competitiveness[78]. - The company is expanding its portfolio with new projects aimed at treating various diseases, enhancing its market position and economic prospects[78]. - The company is enhancing its amino acid chiral source synthesis technology platform through various projects, improving its market competitiveness[81]. - Research and development expenses increased by 30% in 2022, totaling 450 million RMB, to support new technology advancements[200]. Governance and Compliance - All board members attended the meeting to review the annual report, indicating strong governance practices[5]. - The company has established a complete governance structure with specialized committees, including the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategy Committee, ensuring compliance with legal and regulatory requirements[124]. - The company maintains full independence in assets, personnel, finance, organization, and business operations, with no shared resources with controlling shareholders[126]. - The company has a complete and independent financial accounting system, with separate bank accounts and tax registration, ensuring independent financial decision-making[128]. - The company has not reported any penalties from regulatory authorities for its directors or management in the past three years[144]. Environmental Responsibility - The company reported a wastewater discharge of 185,777.3 tons in 2022, a decrease of 27.39% compared to 2021[171]. - The company has implemented various pollution control measures in compliance with national standards[170]. - The company has invested approximately ¥30,797,707.82 in environmental protection and management during the reporting period[188]. - The company achieved a COD removal efficiency of 93.74% and a VOCs removal efficiency of 98%[1]. - The company has a comprehensive self-monitoring plan in place, ensuring compliance with relevant laws and regulations[173]. Employee Management and Development - The company has a total of 504 employees at the end of the reporting period, with 325 in production, 115 in technical roles, and 50 in administration[155]. - The company established a performance-based compensation system that links employee salaries to company performance and individual contributions[156]. - The company has a training system that includes both internal and external training programs aimed at enhancing employee skills and organizational capabilities[157]. - The number of R&D personnel increased by 37.70% from 61 in 2021 to 84 in 2022, with a 3.44% rise in the proportion of R&D staff[84]. Strategic Initiatives - The company plans to enhance its supply chain management, aiming for a 20% improvement in delivery times[138]. - The company plans to invest 200 million RMB in digital transformation initiatives over the next two years[200]. - The company aims to strengthen its human resource management to support its development strategy and improve talent acquisition and retention[115]. - The company will continue to optimize its operational mechanisms and improve efficiency through digital transformation and enhanced management systems[115].

诚达药业股份有限公司 2023 年第一季度报告 证券代码：301201 证券简称：诚达药业 公告编号：2023-018 诚达药业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 诚达药业股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 102,199,584.64 | 108,619,193.47 | -5.91% | | 归属于上市公司股东的净利 | ...

编号：2022-002 证券代码：301201 证券简称：诚达药业 诚达药业股份有限公司 投资者活动记录表 | --- | --- | --- | |-------------------|---------------------------------------------------------------------------------|------------------------------------------------------------| | | | √特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | □电话会议 | | | □其他： | （请文字说明其他活动内容） | | 参与单位名称 | 光大证券：林小伟、曹聪聪 | | | 及人员姓名 | 国泰基金：叶烽、姜英、任一林 | | | 时间 | 2022 年 6 月 10 日 10:00-11:00 | | | | | | | 地点 | 公司会议室（腾讯视频会议） | | | 公司接待人员 姓名 | 董事长：葛建利 ...